Engineered Immune Cells Show Promise in Halting Dangerous Heart Scarring
Lesion-targeted immune modulation is a feasible strategy to control cardiac fibrosis, and engineered dendritic cells are a promising therapeutic platform for treating cardiac remodelling and heart failure.
Scientists have developed a novel approach to combating cardiac fibrosis using engineered immunosuppressive dendritic cells, with new research suggesting these modified immune cells can effectively protect the heart from damaging structural changes known as cardiac remodelling.
Cardiac remodelling, a process in which the heart undergoes harmful structural and functional changes following injury or chronic stress, is a key driver of heart failure. The buildup of scar tissue, or fibrosis, within the heart muscle stiffens the organ and impairs its ability to pump blood efficiently, contributing to millions of deaths worldwide each year.
The research centers on dendritic cells — immune cells that play a central role in regulating the body's immune responses. By engineering these cells to suppress inflammation specifically at the site of cardiac lesions, researchers demonstrated that it is possible to control the fibrotic process without broadly dampening the immune system.
Lesion-targeted immune modulation proved to be a feasible and effective strategy in preclinical models, with the engineered dendritic cells successfully reducing fibrotic tissue accumulation and preserving heart function. The targeted approach minimizes the risks typically associated with systemic immunosuppression, such as increased susceptibility to infection.
Researchers say this platform represents a significant step forward in the development of cell-based therapies for cardiovascular disease. Unlike conventional drug treatments that offer limited ability to target specific tissue sites, engineered dendritic cells can be designed to home in on areas of active inflammation and scarring.
The findings position engineered dendritic cells as a promising therapeutic platform not only for cardiac remodelling but potentially for other fibrotic diseases across multiple organ systems. Scientists are now calling for further studies to advance this technology toward clinical trials in human patients.